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Abstract
Background: Epilepsy affects an estimated 50 million people and accounts for approximately 1% of days lost to ill
health globally, making it one of the most common, serious neurological disorders. While there are abundant
global data on epilepsy incidence, prevalence and treatment, there is a paucity of Australian incidence data. There
is also a general lack of information on the psychosocial impact and socioeconomic consequences of a new
diagnosis of epilepsy on an individual, their family, household, and community which are often specific to the
health and social system of each country.
Methods/Design: The Sydney Epilepsy Incidence Study to Measure Illness Consequences (SEISMIC) is an Australian
population-based epilepsy incidence and outcome study that will recruit every newly diagnosed case of epilepsy in
the Sydney South West Area Health Service to an epilepsy register. Multiple and overlapping sources of notification
will be used to identify all new cases of epilepsy over a 24 month period in the Eastern Zone of the Sydney South
West Area Health Service (SSWAHS) and follow up will occur over 12 months. SEISMIC will use the International
League Against Epilepsy (ILAE) definitions and classifications for epidemiologic studies of epilepsy. The study will
examine outcomes including mood, quality of life, employment, education performance, driving status, marital and
social problems, medication use, health care usage, costs and stigma.
Discussion: This study is designed to examine how clinical, psychological factors, socioeconomic circumstances,
and healthcare delivery influence the experience of epilepsy for individuals and families allowing better targeting
of specific services and informing policy makers and practitioners. In addition, the study will provide the basis for a
longitudinal population-based cohort study and potentially inform qualitative sub-studies and randomised
controlled trials of intervention strategies. The study has been registered on the Australia New Zealand Clinical Trial
Registration database with ANZCTRN12609000059268.
Background
Currently there is very limited evidence about the bur-
den of epilepsy in the Australian population. The best
available estimates based on a cross sectional survey in
Tasmania and a study conducted 30 years ago suggest
that it is prevalent in between 6 and 7.5 per 1000 people
[1,2]. This equates to approximately 150,000 people in
Australia presently living with this condition making it
one of the 50 leading causes of disease burden and
injury in the country [3]. Globally about 50 million
people are affected by epilepsy, which accounts for
about 1% of days lost to ill health globally [4]. The aver-
age incidence across developed countries has been esti-
mated at 43.4/100,000 [5] which would suggest that
over 8,800 Australians develop the condition every year.
Despite the potential magnitude of the burden of epi-
lepsy, population-based Australian data on the natural
history of epilepsy are limited, and strategies to reduce
the considerable psychosocial and economic impact of
epilepsy are lacking, or poorly understood.
Epilepsy is a chronic neurological disorder with the
fundamental characteristic of recurrent, intermittent sei-
zures unprovoked by any acute medical condition or
transient brain disorder. A diagnosis of epilepsy is made
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a second unprovoked seizure occurring at least 24 hours
after the first. However “epilepsy” incidence studies have
used varying definitions, often including people with sin-
gle seizures.
Age-specific incidence of epilepsy is bimodal: it is high
in those aged over 60 years and highest in children and
adolescents, with a slight predominance in males [5,6].
However, it is commonly thought that incidence rates
are underestimated in the elderly due to incomplete
case ascertainment in studies. Three recent studies have
demonstrated a higher incidence in lower income
groups in the United Kingdom, New York and Iceland
[7-9] and incidence appears to be higher in developing
countries [5].
Epilepsy is associated with increased mortality [10],
including increased risk of sudden unexpected death
(SUDEP) [11], and morbidity: this may be physical (e.g.
fractures, scalding, bruising) occurring directly as result
of seizures, cognitive (e.g. cognitive delay, speech or lan-
guage difficulties, learning disabilities), behavioural (e.g.
aggression) [12,13], or psychosocial (e.g. depression,
anxiety, stigma).
Seizure Treatment
The goal of initial treatment is to achieve seizure con-
trol by preventing seizure recurrence and maintaining
optimal physical, cognitive, behavioural and emotional
function. Approximately 60-70% of people with new
onset epilepsy become, and remain, seizure free with
appropriate medication [14]. In many of these cases
drug treatment can be withdrawn after seizure remis-
sion, although the risk of relapse remains high [15].
H o w e v e r ,a b o u to n et h i r do fi n c i d e n tc a s e sh a v er e c u r -
rent seizures [6]. The longer term influence of antiepi-
leptic drugs is unknown [16]. Despite the magnitude of
the problem, and the effectiveness and relatively low
cost of treatment, many patients may not receive effec-
tive treatment through lack of adherence to medication,
reduced availability of diagnosis and drugs e.g. living in
a rural area or inability of the individual or health sys-
tem to pay for treatment, such as in a low income coun-
try [17]. Further, there may be delays in seeking help
due to ignorance, fear, stigma [18], illiteracy and cultural
attitudes towards treatment (e.g. attributing epilepsy to
possession).
The psychosocial impact of epilepsy
T h es o c i a ls e q u e l a eo fe p ilepsy are far reaching and
potentially include the loss of a driving licence, lack of
access to or change in employment or education cir-
cumstances, marital and social problems, taking regular
medication and dealing with the responses of others to
the diagnosis including perceiving and experiencing
stigma and discrimination [18]. Reduced social participa-
tion, physical inactivity, and higher healthcare usage are
also more common in people with epilepsy [19]. As a
group, people with epilepsy have poorer psychosocial
functioning than those without epilepsy [20].
Psychological comorbidities such as anxiety, depres-
sion [21-23] and sleep disturbance [24] are common in
people with epilepsy, and increase the risk of suicide
[25]. Lifetime prevalence estimates of major depressive
disorder are as high as 17.4% (95% CI 10-24.9), mood
disorders 24.4% (16.0-32.8) and anxiety disorders 22.8%
(14.8-30.9) in people with epilepsy, who were more than
twice as likely than people without epilepsy to report
such disorders [26]. Problems in the areas of attention,
cognition and socialisation are also apparent in children
with epilepsy [27].
Psychosocial sequelae have a greater impact on health-
related quality of life (HRQoL) than short-term seizure
control [28,29]. Veterans with epilepsy with a comorbid
psychiatric diagnosis (depression, anxiety, substance
abuse or post traumatic stress disorder) had HRQoL
scores 24% lower on all eight domains the SF-36 than
veterans with epilepsy alone [30]. People with epilepsy
and depression are more likely to report having seizures
than those without depression [31] and seizure activity
explains much of the variation in psychosocial function-
ing [22]. Whilst more frequent seizures are associated
with impaired HRQoL, and even infrequent seizures
(less than one per year) impair HRQoL in older adults,
stigma is found to be the strongest predictor of reduced
HRQoL [20,29,32]. Despite psychosocial impairment
accounting for a large proportion of the negative out-
comes experienced by people with epilepsy, there has
been little investigation into the natural history of these
psychosocial problems [33]. While the data are limited,
there may be some association between marital (unmar-
ried/separated/divorced) [31,34] and employment
(unemployed) [31,34] status, increasing number of medi-
cal problems [31], lower education, income [35], activity,
social support and increased stigma [34] and the risk of
depression.
The development of interve n t i o n si nt h i sa r e al a g s
behind pathophysiological and pharmacological research.
It has been postulated that stigma may be moderated by
individual resilience-based factors such as self esteem
and social support which, if confirmed, offer promising
areas for intervention [36]. However, there is also little
information on the nature of social support required by
patients, or the impact of epilepsy on carers, the family
or the household.
The economic impact of epilepsy
There are limited data on the economic impact of epi-
lepsy on the individual, their family or the community.
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lyses to measure psychosocial and other subjective
patient-reported outcomes [37], economic data collected
to date are limited to socioeconomic disparities in inci-
dence, epilepsy-related health service costs and gaps in
delivery of appropriate treatment [8,17,38]. It is possible
that socioeconomic disparities in incidence (increased
incidence with more socioeconomic deprivation) may be
a result of confounding [8]. The highest expenditure for
the household of individuals with epilepsy appears to
occur in the first year after diagnosis which reflects
higher use of specialist services over that period [38].
However, when considering costs to a country, a large
proportion of the burden comes from indirect costs
such as unemployment and early mortality [39]. There
is an urgent need for reliable information on the direct
and indirect costs of the condition and for a better
understanding of the factors that are associated with
adverse economic outcomes for patients, their families
and the community.
Australian data
A high quality longitudinal, prospectively recruited popu-
lation-based sample of Australians with incident epilepsy
is lacking. The limited Australian epidemiological epi-
lepsy data are predominantly from cross-sectional sur-
veys of people currently accessing health care for
epilepsy, in addition to some early studies of Sydney gen-
eral practitioners’ knowledge of, management of and atti-
tudes towards epilepsy [40]. An early Sydney study using
‘3 or more seizures verified by a doctor’ to define epilepsy
found a prevalence of 7.5 per 1,000, with remission (30%
off medication) and medication usage (70%) as the pri-
mary endpoints [1]. This prevalence estimate was
adjusted to 1 in 50 in a subsequent analysis [41]. A retro-
spective study on SUDEP in Victoria [42] which led to a
prospective case-cohort coronial deaths study of SUDEP
found that young people with epilepsy are more likely to
die in their sleep than their counterparts [43]. More
recently a survey of Tasmanian residents on the Austra-
lian National prescription database who had been pre-
scribed an antiepileptic drug for epilepsy or seizures was
conducted. This study showed that one quarter of partici-
pants reported very high levels of psychological distress
from anxiety and mood disorders, with this group also
having higher usage of healthcare services [44].
Scientific rationale for a study of newly diagnosed
epilepsy in Australia
The gold standard study design to determine the true
impact of epilepsy is a large-scale, longitudinal, prospec-
tive, population-based incidence and outcome study
which allows observation of the natural history of all
aspects of epilepsy across the age and severity spectrum.
Such a design will enable identification of potentially
modifiable determinants of outcome including
clinical, psychological, social and economic factors
that reduce vulnerability or enhance resilience to
the psychosocial and socioeconomic consequences of
epilepsy in Australia.
Methods/Design
Design and Overview
The Sydney Epilepsy Incidence Study to Measure Illness
Consequences (SEISMIC) is a prospective, population-
based epilepsy incidence and outcome study with study
registration number ACTRN12609000059268. The pri-
mary aim of SEISMIC is to identify modifiable factors
that enhance resilience and reduce vulnerability to the
socioeconomic impact of epilepsy in an Australian
population. We hypothesise that a) psychological factors
(depressive and anxiety symptom burden, and coping)
are associated with socioeconomic outcomes (school
performance, work absence, family impact and economic
hardship), and b) social and economic deprivation, and
service access factors are associated with variation in
disability and clinical outcomes from epilepsy.
Study Population
Inclusion criteria
The population to be surveyed and monitored includes
people more than 44 weeks post conception (i.e. exclud-
ing neonates) fulfilling all of the following criteria:
￿ New diagnosis of epilepsy, and
￿ Residing within the SSWAHS Eastern Zone geogra-
phical boundaries for the past month
￿ They or their “responsible person” (relative/friend)
are able to provide written informed consent. Partici-
pants with a severe language disorder or cognitive
impairment (as indicated by their clinician) are eligible
to take part in the study providing their relative/friend
is able to provide written informed consent and com-
plete the assessments on the participant’s behalf), and
￿ Consent is given to contact the GP if necessary in
the case of a severe psychiatric disorder warranting
treatment.
Exclusion criteria
￿ Seizures due to acute cerebral insult or reversible
metabolic courses.
Population Base
The population to be surveyed and monitored includes
t h o s ew h oa r eu s u a l l yr e s i d e n ti nt h eE a s t e r nZ o n eo f
the SSWAHS http://www.sswahs.nsw.gov.au. In 2006
the estimated resident population of the SSWAHS was
510,000 people, and comprised 7 local government
areas. Children under the age of 15 constitute 16% of
the population; people aged 65 years and over make up
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population. This area is characterized by its multicul-
tural character, with 39% speaking a language other
than English at home. Furthermore this population has
some of the poorest communities in the State, charac-
terized by a large number of recent migrants, signifi-
cantly higher unemployment and a high proportion of
families dependent on welfare. Overall 40% of the area’s
population live in rented accommodation. The following
hospitals or health-care centres are either in the Eastern
Zone of the SSWAHS or treat people with epilepsy who
reside within the catchment area: Bankstown Hospital,
Brain and Mind Research Institute, Concord Repatria-
tion Hospital, Prince of Wales Hospital, Royal Prince
Alfred Hospital, St Vincent’s Hospital, Sydney Children’s
Hospital at Randwick, Westmead including Westmead
Children’s Hospital. The rooms of private epileptolo-
gists, neurologists and paediatricians will also operate as
recruiting sites.
Case ascertainment and consent
The lead clinician at each public or private site will act
as the “principal investigator” (PI). The PI will be
required to consent potentially eligible cases, or their
parent (for potential cases aged 18 years or under), or
guardian (for potential cases unable to consent them-
selves) of people with new diagnoses of epilepsy into the
study. Each PI will maintain a log of every potentially
eligible patient who is approached to participate in the
study. The logs contain the initials and date of birth of
the eligible patients, the date they were screened for
participation in the study, whether or not consent to
participate was obtained and if not, the reason for their
non-participation. Participants consent to: 1) the
abstraction of information about their epilepsy from
medical records; 2) interviews at baseline (as soon as
possible after diagnosis), four months and one year (pri-
mary endpoint), and; 3) for the participant’s general
practitioner (GP) to be contacted by research staff if
necessary. All PIs or their research staff are contacted
weekly to track screening and recruitment.
To ensure identification of all people with a new diag-
nosis of epilepsy in the SSWAHS who are not seen in a
public hospital, regular liaison and collaboration with
General Practitioners (GP), paediatricians and private
neurologists in the area is essential. Various methods
will be used to initiate and maintain a high level of
awareness of the study in the community, including
6 monthly contacts to enquire about potentially eligible
participants, and provision of pamphlets, magnets, pos-
ters and training for clinicians and allied health
professionals.
In addition PIs may consent participants with their
first unprovoked seizure, who do not currently meet the
criteria for a diagnosis of epilepsy, into the SEISMIC
First Seizure substudy. These people will be asked to
allow 6 monthly contact from the research team to
ascertain if there has been any clinical changes that
would warrant their subsequent inclusion as a case of
new onset epilepsy over the course of the study’s
recruitment.
Assessments and data collection
The detailed schedule for data collection is shown in
Table 1. Researchers will travel to the recruitment site
of consented participants and abstract the following data
from consented participants’ medical notes: initials, date
of birth, sex, contact information, source of notification
(hospital, private site, general practitioner etc) and clini-
cal information. Data are entered onto electronic case
report forms (eCRFs) and uploaded to a secure centra-
lised database.
Baseline interview
This will be conducted through a structured face to face
interview by a trained researcher at a place of the parti-
cipant’s or their family’s convenience. Participants com-
plete a clinical and an age-specific psychosocial
assessment.
The clinical assessment for all participants, or their
parent, proxy, carer or guardian includes a clinical and
modified-Austin interview [45]. This questionnaire col-
lects information on epilepsy onset and prodromal char-
acteristics, seizure type classification and syndromal
classification, complete description of seizure: type,
duration, and frequency; other ictal phenomena such as
falls; and duration of post-ictal recovery, any symptom
side effects if prescribed antiepileptic drugs, details of
neurological investigation results (e.g.: EEG, MRI etc)
and medical factors potentially associated with morbid-
ity including comorbidity, family history and potential
aetiological factors e.g. head injury, birth asphyxia.
Following completion of the clinical assessment, parti-
cipants or their proxy complete either the adult/
guardian or the parent/carer of a child assessment as
appropriate.
The adult psychosocial interview with participants who
are 18 years of age or older consists of detailed demo-
graphic, psychosocial and socioeconomic questions
including: duration of residence in Australia, physical
and social living situation, medical history, general well-
being, education and employment, household financial
circumstances, transport, social support, mood, stigma
and sleep. At the end of the interview, all participants
are given the opportunity to provide any other informa-
tion about their experience or circumstances that has
not been covered during the interview.
The parent or carer psychosocial interview for partici-
pants who are between 0 and 18 years of age consists of
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Participant Assessment
a Baseline
b 4 month 12 month
Initials X
Date of birth X
Sex X
Inclusion criteria X
Contact information X
Interview Characteristics
Method of assessment X X X
Participant or proxy XXX
Alive at scheduled time of assessment X X X
Telephone Interview for Cognitive Status (TICS) [63] X X X
Seizure characteristics [45]
Consciousness X
Onset X
Frequency XXX
Phenomena XXX
Precipitants X
Family history X
Epilepsy-related medical history X
New medical problems XX
Modified Cumulative Illness Rating Scale [66] X X X
Birth History X
Medication XXX
Investigations (EEG, CT, MRI etc) X X X
Accidents/falls/injuries XX
Access to services XX
Final diagnosis X
Developmental milestones X
c X
c
Cognitive assessment (optional) XX
Demographic characteristics
Born in Australia X
Years lived in Australia X
Language other than English spoken at home X
Marital status XXX
Number of financially dependent children X
Social/financial living status X X X
Medical History
Psychotropic medications X X X
Brief Illness Perceptions Questionnaire [48] X X X
WHO Disability Assessment Schedule [67] X
a X
a X
a
Strengths and Difficulties Questionnaire [50] X
c X
c X
c
Alcohol consumption: Audit Alcohol Use Disorders Identification Test (AUDIT-C) [51] X
a X
a X
a
Education and Employment
Highest qualification XXX
Current student XXX
Absences from education X X X
Lifetime occupation XXX
Current occupation XXX
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questions about childcare. Adolescents (between 11 and
18 years of age) and children (between 5 and 10 years of
age) also complete age-specific quality of life question-
naires. At the end of the interview, all participants are
given the opportunity to provide any other information
about their experience or circumstances that has not
been covered during the interview.
4 month interview
Participants complete a clinical and an age-specific psy-
chosocial assessment covering the four month period
since their diagnosis. The clinical assessment for all
participants consists of a review of seizure frequency
since last interview, clinical investigations, medications,
general health, developmental milestones and an
optional cognitive assessment if deemed necessary by
the interviewer. The adult, parent or carer interviews are
as outlined previously.
12 month interview
Participants complete a clinical and an age-specific psy-
chosocial assessment covering the previous 8 month
period. The clinical assessment for all participants is as
outlined at the four month assessment with a reassess-
ment of the diagnosis of epilepsy or epilepsy syndrome.
Table 1 Schedule of assessments in the SESIMIC study (Continued)
Job content questionnaire [53] X
a X
a X
a
Financial Situation
Household benefits XXX
Main source of income X X X
Insurance XXX
Economic hardship XXX
Income XXX
Transport
Vehicles driven and frequency X
a X
a X
a
Transport to work/education X
a X
a X
a
Drive for work X
a X
a X
a
Childcare
Location X
c X
c
Duration X
c X
c
Absence from childcare X
c X
c
Support
Confiding relationship XXX
Family adaptation, partnership, growth affection, resolve questionnaire [55] X X X
Inventory of Family Protective Factors [56] X X X
Social media use XXX
Mood
Hospital Anxiety and Depression Scale [57] X
a X
a X
a
General Health Questionnaire X
c X
c X
c
Stigma
Modified HIV Stigma Scale [59] X X X
Disclosure of epilepsy diagnosis X X X
Sleep
Pittsburgh Sleep Quality Index [60] X X X
Health related quality of life
EuroQol [47] X
a X
a X
a
Quality of Life in Epilepsy for Adolescents [61] X
b X
b X
b
Longitudinal Study of Australian Children [62] X
d X
d X
d
a Adult only (> 18 years of age).
b Adolescent only (11-18 years of age).
c Child only (< 18 years of age).
d Young child (5-10 years of age).
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previously.
Specific questionnaires used include
The EuroQol (EQ-5D) [46,47] is a measure of quality of
life that provides a simple descriptive profile and a sin-
gle value for health status graded on a scale from -0.59
to 1.00. Lower scores indicate poorer quality of life.
A score of 0 represents no quality of life and scores less
than 0 represent states perceived by the respondent to
be worse than death.
The Brief Illness Perception Questionnaire (BIPQ) [48]
is a valid and reliable measure of patients’ cognitive and
emotional representations of their illness across a variety
of illness groups. The BIPQ assesses consequences,
timeline, personal control, treatment control, identity,
coherence, concern, emotional response, and causes
of illness. Items are rated using a 0 (not at all) to
10 (severely affects my life) response scale.
Psychosocial disability is assessed using the 12-item
World Health Organisation Disability (WHO) Assess-
ment Schedule (WHO-DAS II) [49]. The 12-item
WHO-DAS II assesses the magnitude of disability over
the previous 30 days using a five point scale from none
to extreme/cannot do. Total scores range from 0-100
with higher scores indicating greater disability.
The Strengths and Difficulties Questionnaire (SDQ) [50]
is a brief behavioural screening questionnaire for parents
of 4 to 16 year olds which screens for child psychiatric dis-
orders. In addition to assessing common emotional and
behavioural difficulties, it also asks if the parent/carer/
proxy thinks that the child has problems in these areas
and if there is associated distress and social impairment.
The SDQ consists of 5 domains with 5 items per domain
with responses ranging from 0 (not true) to 2 (certainly
true) with higher scores indicating more problems.
The Alcohol Use Disorders Identification Test
(AUDIT-C) [51] uses three questions to collect informa-
tion on ‘at-risk’ alcohol consumption. Individual ques-
tion scores range from zero to four. At risk alcohol
consumption is indicated by a total score of five or
more for males or four or more for females.
Information on paid and unpaid work is collected
using modified versions of questions 34-51 of the Aus-
tralian Bureau of Statistics 2006 Census [52] relating to
jobs and work. Participants are asked to indicate
whether there has been any change in employment cir-
cumstances since their diagnosis. Specific barriers to
return to work are determined using the short form of
the Job Content Questionnaire (JCQ) [53]. This widely
used measure assesses job demands, control over work
and support received.
Household economic hardship is determined by a ser-
ies of questions about failure to make household pay-
m e n t sa n dw h e t h e rt h e r ew a sh e l pp r o v i d e db ya n y
organisation or individual to meet these payments. An
advantage of this measure is that it is sensitive to the
possibility that individuals prioritise certain payments
(e.g. default on power bills to pay rent). The basis for
these questions is the US Census Survey of Income and
Program Participation [54].
The Family Adaptation, Partnership, Growth, Affec-
tion, Resolve (APGAR) [55] questionnaire is a valid and
reliable 5-item instrument for assessing perceptions of
adequacy of social support among adults and children.
Items are rated using a three point scale from ‘hardly
ever’ to ‘almost always’. Total scores range from 0 (per-
ceives inadequate support) to 10 (perceives adequate
social support).
The Inventory of Family Protective Factors (IFPF) [56]
is a 16-item scale which assesses stressful events the
family may have experienced and how they were
handled. Item scores range from 1 (not at all like my
family) to 5 (almost always like my family). Total scores
range from 16 to 80 with high scores indicating a per-
ceived high degree of protection provided by the family.
The Hospital Anxiety and Depression Scale (HADS) [57]
is used to collect information on depression and anxiety.
T h eH A D Si sas e l f - r e p o r ti n s t r u m e n td e s i g n e df o ru s e
with medically ill patients. Scores of 8 (possible range
0-21) or more on the depression or anxiety subscales are
classified as ‘depressed’ or ‘anxious’, respectively. Consent
has been obtained to convey scores of 8 or more directly
to participants’ nominated GP who will be permitted to
arrange treatment or formal referral for abnormal mood
symptoms according to their clinical judgement.
The General Health Questionnaire (GHQ-12) [58]
assesses psychiatric morbidity including general level of
happiness, experience of depressive and anxiety symp-
toms, and sleep disturbance over the last four weeks. The
four-item responses range from 0 (not at all) to 1 (much
more than usual) with bimodal item scoring. Total scores
range from 0 to 12 with scores of 4 or more considered
experiencing high psychiatric morbidity.
The HIV Stigma Scale [59] has been modified for use in
people with epilepsy. This scale assesses 1) Personalized
stigma: consequences of other people knowing they have
epilepsy 2) Disclosure concerns 3) Negative self image:
not as good as others, shame, guilt and 4) Public atti-
tudes: what people think about epilepsy. The four-item
responses range from 1 (strongly disagree) to 4 (strongly
agree) with total scores ranging from 10 to 40 with lower
scores indicating less experienced or perceived stigma.
The first seven items of the Pittsburgh Sleep Quality
Index (PSQI) [60] are used to measure sleep quality
over the previous month. Item responses range from
0 (not during the past month) to 3 (three or more times
per week) with higher scores indicating more sleep
disturbance.
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(QOLIE-AD-48) [61] scale assesses the affects of epi-
lepsy and antiepileptic medications, and daily activities
for adolescents aged between 11 and 18 years of age.
Items are rated on a 5 point scale from 1 (poor/much
worse) to 5 (much better) with higher scores indicating
better health-related quality of life.
Selected sections of questions from the Longitudinal
Study of Australian Children (LSAC) [62] are used to
assess child care, education (use, level, absence and per-
formance) and mood.
The Telephone Interview for Cognitive Status (TICS-
M) [63] has been validated for assessment of cognitive
function for research purposes. The 13-item TICS-M
test includes orientation, recent and delayed memory,
attention and comprehension assessment with a maxi-
mum score of 39. As the TIICS-M can be administered
via the telephone it can be used in people with visual
difficulties or poor hand-eye co-ordination.
Diagnostic committee review
In all cases, information gathered from the treating clin-
ician’s notes through the diagnostic proforma and the
baseline clinical interview with the participant will be
reviewed by the Diagnostic Committee for a final deci-
sion as to the diagnosis. The diagnostic committee com-
prises a panel of Sydney epilepsy specialists. Epilepsy
will be defined according to the ILAE guidelines [64].
A clinical diagnosis will rely upon two criteria:
(a) Clear evidence of recurrent epileptic seizures, with
evidence that these are unprovoked by any acute medi-
cal condition or transient brain disorder; and
(b) Documentation of diagnosis by someone with
appropriate specialized training in the recognition of
epilepsy. This allows for the inclusion of those who have
an enduring predisposition to generate epileptic seizures
yet have only had one seizure.
Each participant will be allocated to one of the follow-
ing groups:
Definite epilepsy, with primary documentation that
meets criteria: a) clear evidence of two or more unpro-
voked epileptic seizures that have occurred over interval(s)
exceeding 24 hours, or b) confirmed diagnosis of epilepsy
by a health care provider with appropriate specialised
training in the recognition and treatment of epilepsy.
Probable epilepsy, with other sources of information
indicating the likelihood that criteria (a) or (b) are met.
Documentation of a diagnosis of epilepsy by a trained
non-specialist health care provider without specific doc-
umentation of definite criteria above.
Possible epilepsy: requires further information from
the baseline interview to confirm this and identify the
seizure type classification.
Other seizure type: provoked seizure (acute symptomatic)
e.g. post acute head injury, non-epileptic non-organic
seizures (panic, psychogenic etc), non-epileptic organic sei-
zures (syncope etc)
Not epilepsy
Statistical considerations
Sample size assumption
In the most recent census [52] there were 510,000 peo-
ple usually resident in the Eastern zone of the SSWAHS.
SEISMIC can expect to recruit 254 people with epilepsy
per year for a total of 508 over the two year recruitment
period. With an estimated 5% refusal, we can expect
484 people to be recruited.
Adults In a Tasmanian cross sectional survey approxi-
mately 30% of adults with epilepsy reported psychologi-
cal morbidity, which is associated with increased
disability (e.g. taking more sickness or disability days).
In an American study having chronic epilepsy and
depression was associated taking 4 more disability days
per month than those without [65]. If we hypothesise
that participants with psychiatric co-morbidity experi-
ence 5 disability days vs. 3 disability days per month for
those without psychiatric co-morbidity and the standard
deviation (SD) of these is 4 then we are looking for an
effect size of 0.5. With 90% power, an alpha of 0.05
would require a sample of 191 (64 with psychiatric co-
morbidity, 127 without) to detect this difference in dis-
ability days per month (total sample 143 at 80% power).
With the incidence assumptions from above, two years
of recruitment would be adequate to detect this in
working age adults and evaluate employment conse-
quences of epilepsy as well as providing some leeway for
multivariate modelling and interactions.
Children In the SSWAHS 39% of families speak a lan-
guage other than English at home. If we hypothesis that
this is associated with a greater economic household
impact through e.g. increased likelihood of not making a
basic household payment, then the sample size recruited
in two years above is sufficient to detect a relative risk
of 1.5 for this poorer socioeconomic outcome.
Statistical Analysis
The incidence of epilepsy will be reported as definite
cases of epilepsy over the population of the study area.
Incidence will also be reported by age and syndromic
groups. Data analysis will use multivariable one-level
(SAS Proc Genmod) as well as mixed model
approaches, which take variations within cluster
(patients) and between clusters (e.g. hospitals) into
account (SAS Proc Mixed). Mixed model approaches
will be of use when cluster and individual level data are
used to explain a possible outcome, for example, pro-
cess of care by hospital along with individual level data
on language spoken at home as risk factors for adher-
ence to medication.
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contributions of protective and risk factors on several
clinical, psychosocial and economic outcomes. Hypothe-
sised and known risk factors from the literature will be
used in the initial regression models, together with fac-
tors with a p-value of less than 0.2 in univariate analyses
which will be considered as potential confounders. Rela-
tive risks and their corresponding 95% confidence inter-
vals will be presented for risk factors as they relate to
the outcomes of interest.
Since the length of follow-up for participants will dif-
fer depending on the date of diagnosis and hence enrol-
ment into the incident cohort, length of time in the
study (and therefore at risk) will be taken into account
in regression models. Potential effect modifiers will be
examined by inserting interaction terms into the multi-
variable models.
Survival analyses will be used to investigate the time
trajectory of risk and protective factors for various poor
outcomes. Kaplan-Meier survival curves will be pro-
duced and then the adjusted survival will be examined
using Cox proportional hazards models in order to take
into account multiple exposure variables.
Ethical approval
Full ethical approval was provided by the Human
Research Ethics Committee/08/RPAH/258 (lead com-
mittee) of the SSWAHS for protocol No X08-0152 on
10
th July 2008 and from local institutional research gov-
ernance offices for each clinical centre or PI. Written
informed consent is obtained for every participant or
their parent, carer, guardian or proxy.
Discussion
Epilepsy is a costly, stigmatized and neglected condition.
With the rapidly changing demographic and ethnic
makeup of the Australian population, a population-
based study of this condition is timely. Through SEIS-
MIC the rates of different epilepsy syndromes, overall
and by sex and age group, will be determined for Aus-
tralia. A feature of this study is its multidisciplinary
approach in assessing the impact of epilepsy on indivi-
duals, their families and to the community.
SEISMIC will contribute information to promote a
h e a l t h yl i f eb yp r o v i d i n gi n f o r m a t i o nt h a tw i l lh e l p
address the psychosocial and economic impact asso-
ciated with epilepsy which will ultimately help people
live fulfilling and productive lives. The current paucity
of prospectively collected population-based Australian
data on people with epilepsy hinders the development of
programs to reduce this burden. For the first time, data
on psychosocial well-being, economic hardship, stigma,
and service use following epilepsy will be collected.
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